Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
American Cancer Society Brightedge
BioCentury | Jul 18, 2024
Emerging Company Profile
Clasp: Optimizing T cell engagers for tighter binding, more cancer killing
Launched in March with $150M, Clasp is designing T cell-engaging bispecifics to better fit the immune synapse
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Dec 20, 2022
Deals
Tmunity buyout gives next building block to Gilead’s Kite
Cell therapy business adds armored CAR T platform, handful of therapies, but won’t advance prostate cancer program
BioCentury | Jun 4, 2021
Emerging Company Profile
Interius design: Penn spinout gets specific with in vivo CAR Ts
Emerging Company Profile: Philadelphia cell and gene therapy play has $76M from Cormorant, Fairmount to get to clinic
BioCentury | Nov 2, 2019
Finance
American Cancer Society’s BrightEdge venture fund hoping to do well by doing good
How BrightEdge is leveraging the American Cancer Society brand to invest alongside top-tier VCs
BioCentury | Jul 24, 2019
Financial News
New investors bring key connections to Freenome’s machine learning diagnostics
The multi-analyte cancer screening company sought relationships as it plans a pivotal study
Items per page:
1 - 6 of 6